Liquid Biopsy Market worth $6.25 billion by 2030, growing at a CAGR of 20.39% - Exclusive Report by 360iResearch

The "Liquid Biopsy Market by Biomarkers (Cell-free DNA, Circulating Tumor Cells, Circulating Tumor DNA), Sample (Blood Based, Urine Based), Type, Technology, Indication, End-User, Application - Global Forecast 2024-2030" report has been added to 360iResearch.com's offering.

The Global Liquid Biopsy Market to grow from USD 1.70 billion in 2023 to USD 6.25 billion by 2030, at a CAGR of 20.39%.

Request a Free Sample Report @ https://www.360iresearch.com/library/intelligence/liquid-biopsy?utm_source=openpr&utm_medium=referral&utm_campaign=sample

Liquid biopsy has emerged as an effective and non-invasive alternative to surgical biopsies, allowing medical professionals to provide accurate information about a tumor through a blood sample. They have drastically revolutionized the field of clinical oncology, offering ease in tumor sampling, continuous monitoring by repeated sampling, devising personalized therapeutic regimens, and screening for therapeutic resistance. The world observes an increase in the number of cancer patients with a huge preference for non-invasive diagnostics procedures, including liquid biopsies. The exponential potential of liquid biopsies in cancer detection has led to more research activities being conducted to amplify their usage. However, limited reimbursement offerings for the procedure and stringent regulations regarding their accuracy and usage significantly limit product adoption across hospitals. Product developers are developing a cost-effective line of liquid biopsies and introducing microarrays and next-generation sequencing technologies in these biopsies to improve their operational characteristics. The technology of liquid biopsies is still evolving, and its non-invasive nature promises to open new eras in clinical oncology.

The liquid biopsy market in the Americas and Europe is highly organized, with prominent market players developing advanced liquid biopsy diagnostics and substantial government assistance for cancer research. Several players have also received United States patents for their liquid biopsy technologies, creating an opportunity for growth in this medical approach. The Asia-Pacific nations, including Thailand, Malaysia, the Philippines, Australia, Indonesia, and Singapore, are expanding their healthcare sectors with significant investments to create a strengthened service associated with early cancer diagnostics. In May 2022, the Australian Cancer Research Foundation (ACRF) Child Cancer Liquid Biopsy Program launched a liquid biopsy program in Sydney, representing the cancer sampling and monitoring revolution. Governments in Asia have approved liquid biopsies considering the need to improve cancer diagnosis. In context, the China Food and Drug Administration (CFDA) approved Amoy Diagnostics' EGFR mutation liquid biopsy for use in 2018. Moreover, concerns regarding the prevalence of cancer, growing research initiatives, and the rapidly developing healthcare sector are expected to expand the need for liquid biopsy across the Middle East & Africa.

Market Segmentation & Coverage:

This research report categorizes the Liquid Biopsy Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Biomarkers, market is studied across Cell-free DNA, Circulating Tumor Cells, Circulating Tumor DNA, Exosome, and Extracellular Vesicles. The Cell-free DNA commanded largest market share of 18.33% in 2023, followed by Circulating Tumor DNA.

Based on Sample, market is studied across Blood Based and Urine Based. The Blood Based commanded largest market share of 53.62% in 2023, followed by Urine Based.

Based on Type, market is studied across Assay Kits, Instruments, and Services. The Assay Kits commanded largest market share of 45.07% in 2023, followed by Instruments.

Based on Technology, market is studied across Multi-gene Parallel Analysis using NGS and Single-gene Analysis using PCR Microarrays. The Single-gene Analysis using PCR Microarrays commanded largest market share of 61.61% in 2023, followed by Multi-gene Parallel Analysis using NGS.

Based on Indication, market is studied across Cancer Indication and Non-Cancer Indication. The Cancer Indication is further studied across Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, and Prostate Cancer. The Non-Cancer Indication commanded largest market share of 61.67% in 2023, followed by Cancer Indication.

Based on End-User, market is studied across Academic & Research Centers, Clinical Diagnostic Laboratories, Hospitals, and Physician's Office Laboratories. The Clinical Diagnostic Laboratories commanded largest market share of 44.22% in 2023, followed by Hospitals.

Based on Application, market is studied across Early Cancer Screening, Recurrence Monitoring, Therapy Selection, and Treatment Monitoring. The Treatment Monitoring commanded largest market share of 32.11% in 2023, followed by Early Cancer Screening.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 41.76% in 2023, followed by Europe, Middle East & Africa.

Inquire Before Buying @ https://www.360iresearch.com/library/intelligence/liquid-biopsy?utm_source=openpr&utm_medium=referral&utm_campaign=inquire

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Liquid Biopsy Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in the Liquid Biopsy Market. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

Key Company Profiles:

The report delves into recent significant developments in the Liquid Biopsy Market, highlighting leading vendors and their innovative profiles. These include Angle PLC, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Biocartis NV, Biocept, Inc., CellMax, Inc., Circulogene, Diacarta, Dxcover Limited, Epic Sciences, Exact Sciences Corporation, Foundation Medicine, Inc., Freenome Holdings, Inc., Guardant Health, Inc., Illumina Inc., Inivata Limited by NeoGenomics, Inc., Laboratory Corporation of America Holdings, Lucence Health Inc., LungLife AI, Inc., MDxHealth SA, Menarini Silicon Biosystems Inc., Myriad Genetics, Inc., Natera, Inc., Neogenomics, Inc., OncoDNA, PerkinElmer, Inc., Personalis, Inc., SAGA Diagnostics AB, Strand Life Sciences Pvt. Ltd., Sysmex Corporation, and Tempus.

Key Topics Covered:

1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
6. Liquid Biopsy Market, by Biomarkers
7. Liquid Biopsy Market, by Sample
8. Liquid Biopsy Market, by Type
9. Liquid Biopsy Market, by Technology
10. Liquid Biopsy Market, by Indication
11. Liquid Biopsy Market, by End-User
12. Liquid Biopsy Market, by Application
13. Americas Liquid Biopsy Market
14. Asia-Pacific Liquid Biopsy Market
15. Europe, Middle East & Africa Liquid Biopsy Market
16. Competitive Landscape
17. Competitive Portfolio

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Liquid Biopsy Market?
2. Which are the products/segments/applications/areas to invest in over the forecast period in the Liquid Biopsy Market?
3. What is the competitive strategic window for opportunities in the Liquid Biopsy Market?
4. What are the technology trends and regulatory frameworks in the Liquid Biopsy Market?
5. What is the market share of the leading vendors in the Liquid Biopsy Market?
6. What modes and strategic moves are considered suitable for entering the Liquid Biopsy Market?

Read More @ https://www.360iresearch.com/library/intelligence/liquid-biopsy?utm_source=openpr&utm_medium=referral&utm_campaign=analyst

Contact 360iResearch

Mr. Ketan Rohom
Sales & Marketing,
Office No. 519, Nyati Empress,
Opposite Phoenix Market City,
Vimannagar, Pune, Maharashtra,
India - 411014.
sales@360iresearch.com
+1-530-264-8485
+91-922-607-7550

About 360iResearch

360iResearch is a market research and business consulting company headquartered in India, with clients and focus markets spanning the globe.

We are a dynamic, nimble company that believes in carving ambitious, purposeful goals and achieving them with the backing of our greatest asset - our people.

Quick on our feet, we have our ear to the ground when it comes to market intelligence and volatility. Our market intelligence is diligent, real-time and tailored to your needs, and arms you with all the insight that empowers strategic decision-making.

Our clientele encompasses about 80% of the Fortune Global 500, and leading consulting and research companies and academic institutions that rely on our expertise in compiling data in niche markets. Our meta-insights are intelligent, impactful and infinite, and translate into actionable data that support your quest for enhanced profitability, tapping into niche markets, and exploring new revenue opportunities.

This release was published on openPR.